London, UK – 16 March 2015. Ergomed plc (LSE: ERGO or ‘Ergomed’) is pleased that its group company PrimeVigilance, one of the world’s leading pharmacovigilance and medical information services providers, has been invited to speak at the DIA USA 2015 51st Annual Meeting taking place from 14th to 18th June, 2015. The event will be […]
London, UK – 16 March 2015. Ergomed plc (LSE: ERGO or ‘Ergomed’) is pleased that its group company PrimeVigilance, one of the world’s leading pharmacovigilance and medical information services providers, has been invited to speak at the DIA USA 2015 51st Annual Meeting taking place from 14th to 18th June, 2015. The event will be held at the Walter E. Washington Convention Center in Washington, DC.
Now in its 51st year, the DIA USA Annual Meeting is one of the largest multidisciplinary events that brings together Life Sciences professionals across all disciplines, with a common goal to foster innovation that will lead to the development of safe and effective medical products and therapies for patients.
Dr Joerg Seebeck will join the Clinical Safety and Pharmacovigilance Symposium panel on Wednesday 17th June at 10:30 am on the “Risk of Drug-Induced QT Interval Prolongation by Monoclonal Antibody Medicines: A Review of Data from an EU Database.”
Mr Andrew Harbrow will join the Validation Symposium panel on Wednesday 17th June at 1:30 pm on the establishment of a new Medical Information Database: “To Validate or Not to Validate – That Is the Question.”
Miroslav Reljanovic M.D., CEO of Ergomed said: “PrimeVigilance is a fast growing Ergomed group company that is a committed to patient safety services and is at the forefront of developments in the Pharmacovigilance and Medical Information industry providing quality services and consultancy to our international clients. We are pleased that PrimeVigilance has been invited to speak at one of the largest and most prestigious events in the sector.”
For further information, please contact:
Hume Brophy
Mary Clark, Supriya Mathur and Hollie Vile
Tel: + 44 203 440 5654
E-mail: ergomed@humebrophy.com
Stifel Nicolaus Europe Limited
NOMAD/Broker to the Company
Jonathan Senior, Giles Balleny
Tel: + 44 207 710 7600
PrimeVigilance
Neil Clark, CEO
E-mail: neil.clark@primevigilance.com
About PrimeVigilance
The pharmacovigilance services offered by PrimeVigilance support essential regulatory and scientific elements required to obtain and maintain a product license within Europe. This includes Qualified Persons, a compliant PV System with robust Quality Management, consistent Adverse Event data capture, expedited reporting, literature screening, preparation of Periodic Safety Update Reports, signal detection and evaluation, benefit-risk assessment, Risk Management Planning, compliance auditing, support during crisis and ad hoc consulting assignments. PrimeVigilance also offers a multi-language Medical Information service. PrimeVigilance has grown organically since 2008 and now has approximately 140 staff employed in its main offices in Guildford UK, and Zagreb, Croatia, as well as an international network of consultants. PrimeVigilance is currently providing services across more than 100 countries.
For more information please visit www.primevigilance.com
About Ergomed
Ergomed PLC is a profitable UK-based company, providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 40 countries.
Ergomed provides clinical development, trial management and pharmacovigilance services to over 60 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.
Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.
As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. For further information, visit: https://ergomedplc.com
Forward Looking Statements
Certain statements contained within the announcement are forward looking statements and are based on current expectations, estimates and projections about the potential returns of Ergomed plc (“Ergomed”) and industry and markets in which Ergomed operates, the Directors’ beliefs and assumptions made by the Directors. Words such as “expects”, “anticipates”, “should”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “pipeline” and variations of such words and similar expressions are intended to identify such forward looking statements and expectations. These statements are not guarantees of future performance or the ability to identify and consummate investments and involve certain risks, uncertainties, outcomes of negotiations and due diligence and assumptions that are difficult to predict, qualify or quantify. Therefore, actual outcomes and results may differ materially from what is expressed in such forward looking statements or expectations. Among the factors that could cause actual results to differ materially are: the general economic climate, competition, interest rate levels, loss of key personnel, the result of legal and commercial due diligence, the availability of financing on acceptable terms and changes in the legal or regulatory environment.
These forward-looking statements speak only as of the date of this announcement. Ergomed expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in Ergomed’s expectations with regard thereto, any new information or any change in events, conditions or circumstances on which any such statements are based, unless required to do so by law or any appropriate regulatory authority.
